secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001193125-25-137119
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

All nine proposals approved at NewAmsterdam Pharma 2025 AGM
-----------------------------------------------------------

- Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.
- Dutch statutory annual accounts for FY2024 approved: 83.5M for, 5.6K against.
- Three non-executive directors (Joustra, McKenna, Gulfo) each elected with >79M for votes.
- Michael Davidson reappointed executive director (70.5M for, 9.2M against); James Topper reappointed non-executive.
- Share buyback authorization extended (71.4M for, 12.2M against); say-on-pay approved and set for annual frequency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/0001193125-25-137119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/d933201d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-137119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer